Highlights from IKCSNA24: 20 Posts Not to Miss

The 2024 International Kidney Cancer Symposium: North America (IKCSNA24) held from November 7-9, 2024, at Omni Louisville, Louisville, Kentucky

The International Kidney Cancer Symposium (IKCS) is a leading multidisciplinary event that brings together experts from academia, clinical care, industry, and advocacy to discuss the latest advancements in kidney cancer. Held annually, the symposium focuses on cutting-edge research, emerging treatments, and future directions in care, with an emphasis on collaboration across disciplines.

Celebrating its 25th anniversary marks a major milestone in the symposium’s journey of fostering collaboration and innovation in the fight against kidney cancer.

Key topics include immunotherapy, targeted therapies, clinical trials, personalized medicine, and patient advocacy. The event features educational sessions, networking opportunities, and discussions on improving patient outcomes. IKCS aims to foster collaboration, raise awareness, and advance the standard of kidney cancer care globally.

Tian Zhang:

“Dena Battle eloquent in showing most recent KCCURE survey data — high burden of disease — 52% pts spend several HOURS per day thinking about cancer. While OS is gold standard, we need to think about pts living, not merely surviving.”

KCA:

“Join us in thanking the IKCSNA24 Scientific Planning Committee for their extraordinary work to bring you this program!”

Arpita Desai:

“Fantastic Kidney Cancer Association Young Investigator Panel to kick off Day 1.”

Sumanta K. Pal:

“Love that Julie Gralow (ASCO CMO) not only flew across the country to Kentucky to support Women in KCA, but also spent extensive time at the IKCSNA24 poster session offering advice to the next generation of scholars (incl Nazli Dizman & Daniela V. Castro). An inspirational person indeed!”

Toni Choueiri:

“And it is David Braun (nickname LeBraun) with the KCA Christopher G. Wood Rising Star Award during IKCSNA24 —David, formerly Dana-Farber Lank Center for Genitourinary Oncology, Harvard Medical Schoo now at Smilow Cancer Hospital, Yale School of Medicine is poised to change the field of Kidney Cancer. Save that tweet.”

Sid Sadler:

“10000% A cancer diagnosis doesn’t stop after surgery or treatment. We need this important conversation to happen in kidney cancer at IKCSNA24. Thankful for Dena Battle and Katie Coleman and many more before me bringing this topic in front of doctors”:

Shuchi Gulati:

“Make sure to pick up a signed copy of Katie Coleman‘s book: “Too Young For Cancer” We got ours and I will be sharing with my patients in clinic too.”

Qian Janie Qin:

“Radiomics in kidney cancer- can we go beyond RECIST and extract impactful data from tumor imaging, perhaps by leveraging AI machine learning- great discussion with our radiology/radiation oncology colleagues”

Sumanta K.Pal:

“Comprehensive presentation from Benjamin L Maughan on current and ongoing trials in non clear kidney cancer at IKCSNA24. Ben is PI of SWOG 2200, a study we need support for!”

Nazli Dizman:

“Thanks to IKCSNA24 for prioritizing patient voices!

‘Patient-Centered Outcomes in Kidney Cancer Research’ – Ask patients for their preferred appointment times – Find out what topics they want to discuss with their oncologist – Focus on new metrics to capture patient-centered outcomes – Drive global efforts to understand the burden of cancer worldwide.”

Lauren Meehan Machos:

“25 Years of KCA with amazing Women in RCC together discussing science, mentorship, building careers and most importantly, supporting each other and those diagnosed with kidney cancer ”

Matt Campbell:

“Fantastic Think Tank to start IKCSNA24 on Biomarker development and risk stratification in kidney cancer. Great job by our moderators Daaniel Shapiro and Marie Carlo.”

Sid Sadler:

“Day 2 at IKCSNA24 . So thankful to be given the opportunity to speak in front of giants in the medical community about my kidney cancer diagnosis. So hopeful for the future, and thank you to KCA for the platform to speak. Patient Perspectives Matter.”

Qian Janie Qin:

“Dr. Benjamin L Maughan emphasizing divergent histology RCC as a heterogeneous entity requiring more disease specific targets and trial design/implementation.”

Moshe Ornstein:

“Bradley McGregor discussing a history of treatment options for patients with mRCC with divergent histology. Progress! Trials are doable in this setting.

Great summary slide!”

Daniel Shapira:

“Carrying on Chris wood’s legacy expertly on the annual WOODFIRE Jose Karam, E Jason Abel at the IKCSNA24”

Tian Zhang:

“Vaccines coming for kidney cancer?

Elizabeth Plimack shows prior ADAPT trial and recent data on V940 vaccine — futurescape of vaccines! We have the V940 adjuvant trial open UTSW Simmons Cancer Center led by Hans Hammers.”

Sid Sadler:

“Katie Coleman doing what she does best. Providing an impact and insightful patient perspective at IKCSNA24. These stories are so important to not only doctors and researchers but patients like myself as well. The YA perspective is unique and has many layers. Thank you to the KCA for allowing the patient perspective to be shared with doctors and researchers alike.”

Nazli Dizman:

“Important work by Dr. Pooja Ghatalia at IKCSNA24.

Pooled analysis of safety outcomes with Belzutifan in renal cell carcinoma.”

Qian Janie Qin:

“Congratulations to Dr. Naomi Haas, recipient of the Eugene P. Schonfeld Award KCA IKCSNA24 for her research with a vision for progress in field of kidney cancer.”

Further Reading:

David Braun Receives the Dr. Christopher G. Wood Rising Star Award

Daniel J. George Received KCA’s Nicholas J. Vogelzang Humanitarian Award